Interestingly, several recent studies have shown that SOX10 is preferentially expressed in triple-negative and metaplastic breast carcinomas and has emerged as a useful immunohistochemical marker to utilize in breast pathology practice [61, 62]. This evidence concerns the gene SOX10 and breast carcinoma.